Acrivon Therapeutics, focusing on RAS-driven cancers, is listing shares on Nasdaq, with Jefferies providing investment research.
4 reports, 2 independent
Updated 00:00
Still developing
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acrivon Therapeutics, focusing on RAS-driven cancers, is listing shares on Nasdaq, with Jefferies providing investment research.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Acrivon CEO sold shares to cover tax withholding after listing on Nasdaq.1 source
Jefferies provides research on Acrivon Therapeutics as it lists on Nasdaq.1 source
Keep exploring
The entities involved
-
Jefferies Financial Group
American financial services company
-
Nasdaq
American fully electronic stock exchange